Pyrazine derivatives: a patent review (June 2012 – present)

Bibliography

• Barlin GB. Chemistry of heterocyclic compounds. John Wiley and Sons; New York: 1982
   Google Scholar
• Bird CW. Heteroaromaticity, 5, a unified aromaticity index. Tetrahedron 1992;48:335-40
   Web of Science ®Google Scholar
• Awwadi FF, Landee CP, Turnbull MM, et al. Low-dimensional quantum magnetic systems: synthesis, structure and magnetic behavior of (2,5-dimethylpyrazine)copper(ii) chloride and synthesis and magnetic behavior of bis(2,6-dimethylpyrazine)copper(ii) chloride. Polyhedron 2005;24:2153-9
   Google Scholar
• Joule JA, Mills K. Heterocyclic Chemistry. Wiley-Blackwell; Chichester: 2010
   Google Scholar
• Brown CJIII, Knaust JM. 2,5-Dimethylpyrazine 1,4-dioxide. Acta Cryst Sect E Struct Rep Online 2009;65:o3052
   PubMedGoogle Scholar
• Rajini RS, Aparna P, Sasikala C, Ramana CV. Microbial metabolism of pyrazines. Crit Rev Microbiol 2011;37:99-112
   PubMed Web of Science ®Google Scholar
• Woolfson A, Rothschild M. Speculating about pyrazines. Proc Royal Soc 1990;242:113-19
   Google Scholar
• Maga JA. Pyrazine update. Food Rev Int 1992;8:479-558
   Google Scholar
• Wagner R, Czerny M, Bielohradsky J, Grosch W. Structure-odour-activity relationships of alkylpyrazines. Z Lebensm Unters Forsch A 1999;208:308-16
   Google Scholar
• Kikugawa K. Organochemical studies on the formation and the reduction of mutagenic and/or carcinogenic and the DNA damaging components in foods. Environ Mutagen Res 2004;26:23-31
   Google Scholar
• Dolezal M. Biological active pyrazines of natural and synthetic origin. Chem Listy 2006;100:959-66
   Web of Science ®Google Scholar
• Dolezal M, Zitko J, Jampilek J. Pyrazinecarboxylic acid derivatives with antimycobacterial activity. In: Cardona PJ, Understanding tuberculosis - new approaches to fighting against drug resistance. InTech; Rijeka: 2012
   Google Scholar
• Muller R, Rappert S. Pyrazines: occurrence, formation and biodegradation. Appl Microbiol Biotechnol 2010;85:1315-20
   PubMed Web of Science ®Google Scholar
• Yamaguchi T. The relationship between the chemical structures of dihydropyrazine derivatives and DNA strand-breakage activity. Chem Pharm Bull(Tokyo) 2007;55:532-6
   PubMed Web of Science ®Google Scholar
• Miniyar PB, Murumkar PR, Patil PS, et al. Unequivocal role of pyrazine ring in medicinally important compounds: a review. Mini Rev Med Chem 2013;13:1607-25
   PubMed Web of Science ®Google Scholar
• Achelle S, Baudequin C, Plé N. Luminescent materials incorporating pyrazine or quinoxaline moieties. Dyes Pigments 2013;98:575-600
   Web of Science ®Google Scholar
• Ferreira SB, Kaiser CR. Pyrazine derivatives: a patent review (2008 - present). Exp Opin Ther Pat 2012;22:1033-51
   PubMed Web of Science ®Google Scholar
• Hara T, Norimatsu N, Kurushima H, Kono T. Method for producing dichloropyrazine derivative. US024832; 2014
   Google Scholar
• Wang Y, Wang L, Zhang Q. Synthesis method of pyrazine methylamine derivative. CN103214424; 2013
   Google Scholar
• Chuanbao W. Chiral synthesis of eszopiclone. CN102675318; 2012
   Google Scholar
• Chuanbao W. Method for preparing dexzopiclone. CN102675319; 2012
   Google Scholar
• Yisi F, Fengfeng Z, Zhongqiu X, et al. Synthetic method of bortezomib. CN102659919; 2012
   Google Scholar
• Pi J, Ding Y, Yin D, et al. Novel synthesis route of glipizide. CN102993106; 2013
   Google Scholar
• Mantegazza S, Attolino E, Allegrini P. Process for the preparation of a viral protease inhibitor telaprevir and its intermediates. WO131978; 2013
   Google Scholar
• Nandi S, Sivakumaran M. An improved process for the preparation of telaprevir. IN2012CH04278; 2014
   Google Scholar
• Lehmann F, Bremberg U, Soelver E, et al. Process for manufacturing of kinase inhibitors. WO089636; 2013
   Google Scholar
• Jenmalm JA, Lehmann F, Nilsson BM, et al. Pyrazine derivatives and their use as protein kinase inhbitors. WO095399A2; 2009
   Google Scholar
• Kushner S, Dalalian H, Sanjurjo JL, et al. Experimental chemotherapy of tuberculosis. 2. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 1952;74:3617-21
   Web of Science ®Google Scholar
• Singh SB, Tomassini JE. Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of Influenza virus. J Org Chem 2001;66:5504-16
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Shirakib K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Meyers FJ, Grennan T, et al. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. Invest New Drugs 1998;16:179-82
   PubMed Web of Science ®Google Scholar
• Ambrogi V, Cozzi P, Sanjust P, et al. Anti-lipolytic activity of a series of pyrazine-N-oxides. Eur J Med Chem 1980;15:157-63
   Web of Science ®Google Scholar
• Roblin RO, Williams JH, Winnek PS, English JP. Chemotherapy: II. Some sulfanilamide heterocycles. J Am Chem Soc 1940;62:2002-5
   Google Scholar
• Ambrogi V, Bloch K, Parenti MA, et al. Synthesis of pyrazine derivatives as potential hypoglycemic agents. J Pharm Sci 1972;61:1483-9
   PubMed Web of Science ®Google Scholar
• Adams J, Ma YT, Stein R, et al. Boronic ester and acid compounds. US5780454; 1996
   Google Scholar
• France CP, Winger G, Medzihradsky F, et al. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther 1991;258:502-10
   PubMed Web of Science ®Google Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV. infection. N Engl J Med 2011;25:2417-28
   Google Scholar
• Cragoe EJ. (3-Amino-5,6-disubstituted-pyrazinoyl)guanidines. BE639386; 1964
   Google Scholar
• Foreman MM, Hanania T, Stratton SC, et al. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol Biochem Behav 2008;89:523-34
   PubMed Web of Science ®Google Scholar
• Cotrel C, Jeanmart C, Messer MN. Pyrrolo(3,4-b)pyrazine derivatives. DE2300491; 1973
   Google Scholar
• Clapper ML. Chemopreventive activity of oltipraz. Pharmacol Ther 1998;78:17-27
   PubMed Web of Science ®Google Scholar
• Gluchowski C. 2-Imidazolin-2-ylamino)tetrahydroquinoxalines and methods for using same. EP 0422878; 1991
   Google Scholar
• Pollard JR, Reaper PM, Asmal M. Compounds useful as inhibitors of ATR kinase and combinations thereof for treatment of various diseases such as cancer. WO152298; 2013
   Google Scholar
• Charrier JD, Young SC, Davis CJ, et al. Preparation of pyrazineamine derivatives useful as inhibitors of ATR kinase in the treatment of cancer. WO049719; 2013
   Google Scholar
• Charrier JD, Storck PH, Studley J, et al. Preparation of pyrazineamine derivatives useful as inhibitors of ATR kinase in the treatment of cancer. WO049720; 2013
   Google Scholar
• Charrier JD, Storck PH, Studley J, et al. Preparation of pyrazineamine derivatives useful as inhibitors of ATR kinase in the treatment of cancer. WO049722; 2013
   Google Scholar
• Charrier JD, Studley J, Pierard FYTM, et al. Preparation of aminopyrazine-isoxazole derivatives useful as inhibitors of ATR kinase. WO049726; 2013
   Google Scholar
• Charrier JD, Durrant SJ, Knegtel R. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US20130115310; 2013
   Google Scholar
• Charrier JD, Durrant SJ, Shaw DM. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US0115311; 2013
   Google Scholar
• Charrier JD, Storck PH, Pinder J, Studley JR. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US0115312; 2013
   Google Scholar
• Charrier JD, O’Donnell ME, Everitt SR. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US0115313; 2013
   Google Scholar
• Charrier JD, Kay D. Preparation of pyrazine derivatives useful as inhibitors of ATR kinase. US20130115314; 2013
   Google Scholar
• Charrier JD, Pinder J, Storck PH. Preparation of substituted isoxazolylpyrazinamines as inhibitors of ATR kinase. US0107093; 2014
   Google Scholar
• Charrier JD, Durrant SJ, Kay D, et al. Compounds useful as inhibitors of ATR kinase. US113005; 2014
   Google Scholar
• Pollard JR, Reaper PM. Treating pancreatic cancer and non-small cell lung cancer with ATR kinase inhibitors. WO049859; 2013
   Google Scholar
• Fokas E, Prevo R, Pollard JR, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012;3:e441
   PubMed Web of Science ®Google Scholar
• Song Y, Xu Q, Jia Z, et al. Preparation of pyrazine derivatives for use as Syk kinase activity inhibitors. US0131040; 2013
   Google Scholar
• Boyle RG, Boyce RJ. Pharmaceutically active pyrazine derivatives. WO072502; 2013
   Google Scholar
• Li GQ, Hasvold LA, Tao ZF, et al. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg Med Chem Lett 2006;16:2293-8
   PubMed Web of Science ®Google Scholar
• Collins I, Lainchbury M, Matthews TP, Reader JC. Preparation of 5-(pyridin-2-ylamino)pyrazine-2-carbonitrile compounds as CHK1 inhibitors. WO068755; 2013
   Google Scholar
• Collins I, Lainchbury M, Matthews TP, Reader JC. 5-(pyridine-2-yl-aminop-pyrazine-2-carbonitrile compounds and their therapeutic use. AU2012335409; 2014
   Google Scholar
• Wishart N, Bonafoux DF, Frank KE, et al. Preparation of imidazopyrrolopyrazine derivatives and analogs for use as protein kinase modulators. US0072470; 2013
   Google Scholar
• Wang L, Qi C, He X, Zhang Q. Application of glipizide in preparing medicine for treating tumors. CN103622975; 2014
   Google Scholar
• Lewis RT, Choquette D, Epstein O, et al. Aminodihydrothiazine and aminodioxodihydrothiazine compounds as beta-secretase antagonists and their preparation. WO059185; 2014
   Google Scholar
• Ito Y, Kushida I, Mitasev B. Fused aminodihydrothiazine derivative salts as BACE1 inhibitors and their preparation. WO015125; 2014
   Google Scholar
• Hall A, O’Connor DM. Fused aminodihydrothiazine derivatives. GB2504615; 2014
   Google Scholar
• Hilpert H. Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzoxazinyls as BACE1 inhibitors and their preparation. WO001228; 2014
   Google Scholar
• Borroni E, Gobbi L, Hilpert H, et al. [1,3]Oxazines as BACE inhibitors and their preparation and use as imaging agents and in the treatment of Alzheimer’s disease and diabetes. WO168175; 2012
   Google Scholar
• Le Clerq LC, Bartolome-Nebreda JM, Conde-Ceide S, Van Gool MLM. Inhibitors of phosphodiesterase 10 enzyme. WO009305; 2014
   Google Scholar
• Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006;54:1205-13
   PubMed Web of Science ®Google Scholar
• Bartolome-Nebreda JM, Conde-Ceide S, MacDonald GJ, et al. Preparation of imidazo[1,2–a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases. WO110545; 2011
   Google Scholar
• Bartolome-Nebreda JM, Delgado F, Martin-Martin ML, et al. Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. J Med Chem 2014;57:4196-212
   PubMed Web of Science ®Google Scholar
• Cambell JE, Jones P. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system. WO085284; 2014
   Google Scholar
• Galley G, Norcross R, Pflieger P. Preparation of pyrazine derivatives as inhibitors of TAARs. WO072257; 2014
   Google Scholar
• Graham ES, Ashton JC, Glass M. Cannabinoid receptors: a brief history and "what’s hot". Front Biosci 2009;14:944-57
   Web of Science ®Google Scholar
• Bissantz C, Dhurwasulu B, Grether U, et al. Preparation of novel pyrazine derivatives a CB2 agonist. WO060751; 2013
   Google Scholar
• Dhurwasulu B, Grether U, Nettekoven M, et al. Novel pyrazine derivatives as CB2 receptor agonists. WO086807; 2014
   Google Scholar
• Woodward RM. Use of opioid receptor antagonist for gastrointestinal tract disorders. MX003310; 2012
   Google Scholar
• Bylock LA. Oxadiazoles as inhibitors of leukotriene production for combination therapy and their preparation. WO0195879; 2013
   Google Scholar
• Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21:321-7
   PubMedGoogle Scholar
• Li T, Patel S, Perner RJ, et al. Preparation of octahydropyrrolopyrazine sulfonamide derivatives for use as calcium channel blockers. WO049174; 2013
   Google Scholar
• Gillis EP, Bowsher S, Scola PM. Preparation of peptide hepatitis C virus inhibitors that target NS3 protease. WO071007; 2014
   Google Scholar
• Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 2012;8:15
   Web of Science ®Google Scholar
• Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004;311:929-38
   PubMed Web of Science ®Google Scholar
• Bhalay G, Budd E, Bloomfield GC, et al. Treating diseases mediated by blockade of epithelial sodium channel with pyrazine-2-carboxamide derivatives. US171421; 2014
   Google Scholar
• Bhalay G, Edwards L, Howsham C, et al. Preparation of pyrazine derivatives as epithelial sodium channel blockers. US0113914; 2014
   Google Scholar
• Hamprecht D, Heckel A, Kley J. N-(Pyrazinecarbonyl)guanidines as epithelial sodium channel inhibitors and processes for the preparation thereof. WO174757; 2013
   Google Scholar
• Heckel A, Blum A, Hamprecht D, Kley J. Preparation of heterocyclic compounds for treating lung and airways diseases. US0157981; 2013
   Google Scholar
• Heckel A, Frattini S, Hamprecht D, Kley J. Heterocyclic compounds, medicaments comtaining said compounds use thereof and processes for the preparation thereof. US0109697; 2013
   Google Scholar
• Johnson MR. Preparation of 3,5-diamino-6-chloro-N-(N-(4-(4-(2-hexyl(2,3,4,5,6-penta-hydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide isomers as sodium channel blockers for therapy. WO003386; 2013
   Google Scholar
• Johnson MR. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity. US171447; 2014
   Google Scholar
• Feng T, Sanganee HJ, Wada H. Pyrazine derivatives. US123275; 2013
   Google Scholar
• Berg S, Bergh M, Hellberg S, et al. Discovery of novel potent and highly selective glycogen synthase kinase-3 beta (GSK3 beta) inhibitors for alzheimer’s disease: design, synthesis, and characterization of pyrazines. J Med Chem 2012;55:9107-19
   PubMed Web of Science ®Google Scholar
• Younis Y, Chibale K, Witty MJ, Waterson D. Preparation of aminopyrazine compounds as antimalarial agents for treatment of malaria. WO121387; 2013
   Google Scholar
• Van Voorhis WC, Hol WGJ, Larson ET, et al. Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US018040; 2013
   Google Scholar
• Vidadala RSR, Ojo KK, Johnson SM, et al. Development of potent and selective plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that the transmission of malaria to mosquitoes. Eur J Med Chem 2014;74:562-73
   PubMed Web of Science ®Google Scholar
• Mendez S, Traslavina R, Hinchman M, et al. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 2009;53:5114-21
   PubMed Web of Science ®Google Scholar
• Welch JT, Mendez S, Cynamon MH. Pyrazinamide for immunostimulation and the treatment of leishmaniases. US157396; 2012
   Google Scholar